<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585650</url>
  </required_header>
  <id_info>
    <org_study_id>2006-5092</org_study_id>
    <secondary_id>Amgen Protocol 20060514</secondary_id>
    <nct_id>NCT00585650</nct_id>
  </id_info>
  <brief_title>Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see how well (compared to placebo) Enbrel®&#xD;
      (etanercept) 50 mg twice a week for 12 weeks affects plaque psoriasis of the hands and/or&#xD;
      feet (palmoplantar psoriasis).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter investigation is a 12 week, double-blind, randomized trial of etanercept, 50&#xD;
      mg twice weekly versus placebo in subjects with palmoplantar psoriasis (PPP). Subjects who&#xD;
      meet the eligibility criteria will be randomized to either 50 mg etanercept twice weekly or&#xD;
      placebo. Subcutaneous injections will occur twice weekly at approximately the same time of&#xD;
      day over the 12-week treatment period. The primary efficacy endpoint will be assessed after&#xD;
      12 weeks of treatment. At the end of the first 12 weeks, all patients (both treatment and&#xD;
      placebo arms) will be treated with etanercept 50 mg twice a week (BIW) for an additional 12&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks.</measure>
    <time_frame>Week 12</time_frame>
    <description>Psoriasis area and severity index (PASI) is the most widely used tool for the measurement of severity of psoriasis. This tool is used to assess the skin lesions of the entire body however, the palmoplantar psoriasis severity index (PPPASI) is a modified form of the the PASI that is assessed for skin lesions of the hands and feet only. The severity is estimated by three clinical signs: erythema induration and desquamation. Severity parameters are measured on a scale of 0 to 4, with 4 being the most severe.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etanercept (Enbrel) 50mg twice weekly injections for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Injections twice weekly for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo injections</intervention_name>
    <description>Placebo injections twice weekly for 12 weeks.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe palmar plantar psoriasis based on physician's global assessment&#xD;
             (PGA).&#xD;
&#xD;
          -  Between 18 and 70 years of age&#xD;
&#xD;
          -  Negative urine pregnancy test at screening and at baseline&#xD;
&#xD;
          -  Sexually active men and women of child-bearing potential must agree to use a medically&#xD;
             accepted form of contraception (birth control) during the exclusionary medicine&#xD;
             wash-out period and throughout the study.&#xD;
&#xD;
          -  Ability to self inject study drug or have a designee who can do so&#xD;
&#xD;
          -  Capable of understanding and giving written voluntary informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with Enbrel® (etanercept) or similar drugs&#xD;
&#xD;
          -  Receipt of investigational drugs or &quot;biologics&quot; within 4 weeks of the screening visit.&#xD;
&#xD;
          -  Evidence of skin conditions (e.g. eczema) other than psoriasis that would interfere&#xD;
             with evaluations of the study medication.&#xD;
&#xD;
          -  Receipt of any biologic medication within the previous 6 months that resulted in a&#xD;
             decreased white blood cell count (cells to help fight infections)&#xD;
&#xD;
          -  Ultraviolet light treatment (e.g. UVB, PUVA) within one month prior to study drug&#xD;
             initiation.&#xD;
&#xD;
          -  Receipt of immune-suppressing drugs other than Rheumatrex® (methotrexate) or&#xD;
             Soriatane® (acetretin) within 4 weeks prior to the first dose of study drug.&#xD;
             Medications you would not be allowed to take during this study include for example,&#xD;
             Cytoxan® (cyclosporine), Imuran® (azathioprine), or Sulfazine® (sulfasalazine). If you&#xD;
             remain on Rheumatrex® (methotrexate) (≤25 mg/week) or Soriatane® (acitretin) (≤50&#xD;
             mg/day), you must be considered to have inadequate disease control in the opinion of&#xD;
             the investigator based on physician's global assessment. You must have been on a&#xD;
             stable dose of systemic treatment for at least 1 month prior to the start of the study&#xD;
             medication. You will be required to maintain a stable dose of the systemic treatment&#xD;
             throughout the study.&#xD;
&#xD;
          -  Use of topical steroids in the past 14 days unless they have been used for longer than&#xD;
             14 days and the severity of disease allows entry into study.&#xD;
&#xD;
          -  Systemic steroid use (prednisone, etc).&#xD;
&#xD;
          -  Prior or concurrent use of Cytoxan® (cyclophosphamide).&#xD;
&#xD;
          -  Elevated liver tests; red blood cell count less than normal; decreased platelet count&#xD;
             (cells to help with blood clotting); decreased white blood cell count (cells to fight&#xD;
             infection); kidney insufficiency&#xD;
&#xD;
          -  Any severe adverse event, infection or abnormal laboratory value at the time of the&#xD;
             screening visit that would preclude participation in the study&#xD;
&#xD;
          -  Presence of a severe infection, less than 30 days prior to the screening visit or&#xD;
             between the screening visit and the first dose of study drug&#xD;
&#xD;
          -  Pregnant or breast-feeding females.&#xD;
&#xD;
          -  Significant concurrent medical diseases including: Uncompensated congestive heart&#xD;
             failure (heart is unable to pump as normal): Myocardial infarction (heart attack)&#xD;
             within 12 months of screening period; Unstable or stable angina pectoris (chest pains&#xD;
             related to your heart); Uncontrolled high blood pressure&#xD;
&#xD;
          -  Severe lung disease requiring medical or oxygen therapy&#xD;
&#xD;
          -  History of cancer (other than surgically removed skin cancer and in situ cervical&#xD;
             cancer) within 5 years of the screening visit&#xD;
&#xD;
          -  History of tuberculosis&#xD;
&#xD;
          -  Known to be HIV positive&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Any neurologic demyelinating disease (such as multiple sclerosis or any neurologic&#xD;
             disease causing loss of sensation or loss of normal movement) or seizure disorder&#xD;
&#xD;
          -  Current or history of psychiatric disease that would interfere with ability to comply&#xD;
             with the study protocol or give informed consent.&#xD;
&#xD;
          -  History of alcohol or drug abuse.&#xD;
&#xD;
          -  Not up-to-date with all immunizations in agreement with the current immunization&#xD;
             guidelines&#xD;
&#xD;
          -  Significant exposure to the varicella virus (chicken pox)&#xD;
&#xD;
          -  Guttate or generalized pustular psoriasis&#xD;
&#xD;
          -  Surgery or trauma within a month of baseline considered by the investigator to&#xD;
             represent a significant risk or interfere with patient evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald D Weinstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Irvine Dermatology Clinical Research Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates, PLLC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <results_first_submitted>May 12, 2011</results_first_submitted>
  <results_first_submitted_qc>October 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2011</results_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>palmoplantar psoriasis</keyword>
  <keyword>etanercept</keyword>
  <keyword>Enbrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the dermatology clinics.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects Receiving Etanercept 50 mg Twice Week for 12 Weeks</title>
          <description>Subjects were randomized to receive etanercept 50mg twice weekly injection for 12 weeks. Subjects were then treated for another 12 weeks with etanercept 50 mg twice weekly. An additional follow-up visit performed on week 28.</description>
        </group>
        <group group_id="P2">
          <title>Subjects Receiving Placebo for 12 Weeks</title>
          <description>Subjects randomized to receive placebo injection twice weekly for 12 weeks. All subjects receiving placebo were then crossed over to etanercept 50 mg twice weekly for another 12 weeks. An additional follow-up visit was performed on week 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects Receiving Etanercept 50 mg Twice Week for 12 Weeks</title>
          <description>Subjects randomized to use etanercept 50mg twice weekly for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Subjects Receiving Placebo for 12 Weeks</title>
          <description>Subjects randomized to placebo injection twice weekly for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks.</title>
        <description>Psoriasis area and severity index (PASI) is the most widely used tool for the measurement of severity of psoriasis. This tool is used to assess the skin lesions of the entire body however, the palmoplantar psoriasis severity index (PPPASI) is a modified form of the the PASI that is assessed for skin lesions of the hands and feet only. The severity is estimated by three clinical signs: erythema induration and desquamation. Severity parameters are measured on a scale of 0 to 4, with 4 being the most severe.</description>
        <time_frame>Week 12</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Receiving Etanercept 50 mg Twice Week for 12 Weeks</title>
            <description>Subjects randomized to use etanercept 50mg twice weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Subjects Receiving Placebo for the First 12 Weeks</title>
            <description>Subjects randomized placebo injection for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks.</title>
          <description>Psoriasis area and severity index (PASI) is the most widely used tool for the measurement of severity of psoriasis. This tool is used to assess the skin lesions of the entire body however, the palmoplantar psoriasis severity index (PPPASI) is a modified form of the the PASI that is assessed for skin lesions of the hands and feet only. The severity is estimated by three clinical signs: erythema induration and desquamation. Severity parameters are measured on a scale of 0 to 4, with 4 being the most severe.</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over a 28 week period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subjects Receiving Etanercept 50 mg Twice Week for 12 Weeks</title>
          <description>Subjects randomized to use etanercept 50mg twice weekly for 12 weeks. An additional follow-up visit was performed on week 28.</description>
        </group>
        <group group_id="E2">
          <title>Subjects Receiving Placebo for 12 Weeks</title>
          <description>Subjects randomized placebo injection for 12 weeks. An additional follow-up visit was performed on week 28.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Feldman, MD, PhD</name_or_title>
      <organization>Wake Forest Baptist Health, Department of Dermatology</organization>
      <phone>336-716-3775</phone>
      <email>sfeldman@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

